|
|
|
|
| LEADER |
05969nam a2200625 4500 |
| 001 |
on1090925584 |
| 003 |
OCoLC |
| 005 |
20200326101200.0 |
| 006 |
m o d |
| 007 |
cr |n||||||||| |
| 008 |
190401s2019 mau o 001 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d N$T
|d EBLCP
|d OHS
|d OCLCF
|d OCLCQ
|d OCLCO
|d OCLCA
|d UKMGB
|d UKAHL
|d YDXIT
|d U3G
|d MEU
|d OCLCA
|d GrThAP
|
| 015 |
|
|
|a GBB971900
|2 bnb
|
| 016 |
7 |
|
|a 019369690
|2 Uk
|
| 019 |
|
|
|a 1102426035
|a 1103960144
|a 1136267106
|a 1139523628
|
| 020 |
|
|
|a 9780128177419
|q (electronic bk.)
|
| 020 |
|
|
|a 0128177411
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128177402
|q (print)
|
| 020 |
|
|
|a 0128177403
|q (print)
|
| 035 |
|
|
|a (OCoLC)1090925584
|z (OCoLC)1102426035
|z (OCoLC)1103960144
|z (OCoLC)1136267106
|z (OCoLC)1139523628
|
| 050 |
|
4 |
|a QP702.G577
|
| 072 |
|
7 |
|a SCI
|x 007000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 572.56
|2 23
|
| 245 |
0 |
0 |
|a Glycan and glycosaminoglycans as clinical biomarkers and therapeutics.
|n Part B /
|c edited by Lijuan Zhang.
|
| 260 |
|
|
|a Cambridge :
|b Academic Press,
|c 2019.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Progress in molecular biology and translational science ;
|v volume 163
|
| 520 |
|
|
|a Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part B, Volume 163 in the Progress in Molecular Biology and Translational Science series, provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include an Overview of Fugal Glycan-based Therapeutics, Heparin: An Essential Drug for Modern Medicine, Low Molecular Weight Heparins and Their Clinical Applications, The Clinical Use of Fondaparinux: A Synthetic Heparin Pentasaccharid, Heparinoids as Clinically Used Drugs, Marine Glycan-Derived Therapeutics in China, Efficacy of Heparinoid PSS in Treating Cardiovascular and other Diseases-30 Years Clinical Applications in China, and more.
|
| 500 |
|
|
|a Includes index.
|
| 588 |
0 |
|
|a Print version record.
|
| 505 |
0 |
|
|a Front Cover; Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics -- Part B; Copyright; Contents; Contributors; Preface; Chapter One: Heparin: An essential drug for modern medicine; 1. Introduction; 2. Structure of heparin; 3. The mechanisms of the heparin; 4. Clinical studies of heparin; 4.1. Anti-coagulation activity of heparin; 4.2. Anti-cancer activity of heparin; 4.3. Heparin in inflammatory diseases; 4.4. Heparin in infectious disease; 4.5. Other diseases; 5. Concluding remarks; Acknowledgments; References
|
| 505 |
8 |
|
|a Chapter Two: Low molecular weight heparins and their clinical applications1. Introduction; 2. Structure of LMWHs; 3. Clinical uses of LMWHs; 4. Update on the LMWHs under clinic trials and its potential applications; 4.1. Anti-tumor; 4.2. Anti-viral; 4.3. Anti-inflammation; 4.4. Anti-diabetes-associated complications; 4.5. Other applications; 5. Concluding remarks; Acknowledgments; References; Chapter Three: The clinical use of Fondaparinux: A synthetic heparin pentasaccharide; 1. Structure and mechanism of Fondaparinux; 2. Pharmacokinetics and pharmacodynamics of Fondaparinux
|
| 505 |
8 |
|
|a 3. Clinical application of Fondaparinux3.1. Prophylaxis of VTE; 3.2. Prophylaxis of DVT; 3.3. Other clinical indications; 4. Concluding remarks; Acknowledgments; Conflict of interest; References; Chapter Four: Heparinoids Danaparoid and Sulodexide as clinically used drugs; 1. Heparin and heparinoids; 2. Heparin, low molecular weight heparin, Danaparoid and Sulodexide; 3. Clinical applications of Danaparoid; 3.1. Danaparoid in HIT; 3.2. Danaparoid in DVT; 3.3. Danaparoid in DIC; 4. Clinical applications of Sulodexide; 4.1. Anticoagulant and antithrombotic activity
|
| 505 |
8 |
|
|a 4.2. Prevention of reperfusion injury4.3. Sulodexide in other diseases; 5. Concluding remarks; Acknowledgments; References; Chapter Five: Efficacy of heparinoid PSS in treating cardiovascular diseases and beyond-A review of 31 years clinical exp ... ; 1. Introduction; 2. Preparation, chemical structure, and clinical doses; 3. Clinical uses and efficacy; 4. Adverse reactions; 5. Pharmacodynamics; 6. Pharmacokinetics; 7. Future perspectives; Acknowledgment; Conflicts of interest; References; Chapter Six: Use of fucoidan to treat renal diseases: A review of 15 years of clinic studies
|
| 505 |
8 |
|
|a 1. Introduction2. Preparation and structure of fucoidan; 3. Pharmacology and mechanism of fucoidan; 3.1. Chronic renal failure (CRF); 3.2. Acute kidney injury (AKI); 3.3. Diabetic nephropathy (DN); 4. Clinical uses and efficacy of fucoidan; 5. Future perspectives; Acknowledgments; References; Chapter Seven: Marine glycan-derived therapeutics in China; 1. Introduction; 2. Fucoidan (Haikunshenxi capsules); 2.1. Chemical structure and preparation; 2.2. Pharmacological activities; 2.3. Clinical applications; 3. Chitin ester (PS916); 3.1. Pharmacological activities; 3.2. Pharmacokinetics
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Glycomics.
|
| 650 |
|
0 |
|a Glycoconjugates.
|
| 650 |
|
0 |
|a Biochemical markers.
|
| 650 |
|
2 |
|a Glycomics.
|0 (DNLM)D054794
|
| 650 |
|
2 |
|a Glycoconjugates.
|0 (DNLM)D006001
|
| 650 |
|
2 |
|a Biomarkers.
|0 (DNLM)D015415
|
| 650 |
|
7 |
|a SCIENCE
|x Life Sciences
|x Biochemistry.
|2 bisacsh
|
| 650 |
|
7 |
|a Biochemical markers.
|2 fast
|0 (OCoLC)fst00831950
|
| 650 |
|
7 |
|a Glycoconjugates.
|2 fast
|0 (OCoLC)fst00943768
|
| 650 |
|
7 |
|a Glycomics.
|2 fast
|0 (OCoLC)fst00943787
|
| 655 |
|
4 |
|a Electronic books.
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Zhang, Lijuan.
|
| 776 |
0 |
8 |
|i Print version:
|z 0128177403
|z 9780128177402
|w (OCoLC)1052874139
|
| 830 |
|
0 |
|a Progress in molecular biology and translational science ;
|v v. 163.
|
| 856 |
4 |
0 |
|3 ScienceDirect
|u https://www.sciencedirect.com/science/bookseries/18771173/163
|z Full Text via HEAL-Link
|
